The Age-Related Eye Disease Study 2 (AREDS2) Research Group*
To determine if adding carotenoids and omega-3 fatty acids to the Age-Related Eye Disease Study (AREDS) formulation decreases risk of age-related macular degeneration (AMD) progression, 4203 patients in the AREDS2 trial at risk of developing advanced AMD were randomized to receive the AREDS formulation with lutein + zeaxanthin, docosahexaenoic acid + eicosapentaenoic acid, or both.